Boehringer Ingelheim and Saniona schizophrenia partnership advances to next stage

The firms are ready to take their two-year long collaboration to the next level.

Photo: Saniona / PR

Boehringer Ingelheim and Saniona are advancing to the next stage of their partnership on a drug candidate within the schizophrenia indication, the latter firm announces in a press release on Monday.

According to the company’s founder as well as chief scientific officer, Jørgen Drejer, the collaboration is now ready for a ”hit-to-lead stage,” which follows the successful completion of a target validation, library screening and generation of selective hits.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs